Related Experiment Videos
[Mitral valve prolapse, arrhythmias and sudden death]
J P Fauchier1, D Babuty, L Fauchier
1Service de cardiologie B et laboratoire d'électrophysiologie cardiaque, CNRS UMR 6542, hôpital Trousseau, 37044 Tours.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|February 24, 2001
Summary
Mitral valve prolapse (MVP) affects 2-3% of adults. While generally low risk, severe MVP with mitral regurgitation can increase risks of sudden death, suggesting myocardial disease over valve issues.
Area of Science:
- Cardiology
- Valvular Heart Disease
Context:
- Mitral valve prolapse (MVP) is a common valvular condition.
- Recent publications necessitate a review of MVP concepts.
- Strict echocardiographic criteria define MVP, affecting 2-3% of the adult population.
Purpose:
- To review classical concepts of mitral valve prolapse (MVP) in light of recent publications.
- To clarify the risks associated with MVP, particularly regarding arrhythmias and sudden death.
- To differentiate between direct valvular malformation and myocardial disease as causes of adverse outcomes.
Summary:
- MVP affects 2-3% of adults; arrhythmias are more common, especially with mitral regurgitation.
- Sudden death risk is low (0.1% annually) but higher (0.9-2%) with mitral regurgitation.
- Myocardial disease, often asymptomatic, is increasingly implicated in fatal MVP outcomes, rather than the valve malformation itself.
Impact:
- Physicians should adopt a flexible approach to MVP patient management.
- Low-risk patients with benign symptoms require reassurance.
- High-risk patients, especially those with familial history, syncope, mitral regurgitation, or severe arrhythmias, need close monitoring and active treatment.